Fortrea

Overview

Fortrea is the public CRO spun out of Labcorp’s former clinical-development business. It is a clinical trial services vendor for pharma, biotech, medical-device, and diagnostics sponsors, with Phase I-IV trial execution, FSP, hybrid delivery, clinical pharmacology, regulatory strategy, HEOR, and evidence-generation support.

Fortrea is most relevant when a sponsor needs a large global CRO with public-company visibility, Labcorp / Covance clinical-development heritage, early-phase clinical pharmacology units, and full-service or FSP clinical operations. It is less relevant for launch teams looking for a patient-services stack, specialty pharmacy network, or access hub.

Clinical Trial Capability Model

The framework below standardizes how Rx Almanac evaluates clinical-trial-services capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Fortrea is evaluated as a public CRO spun out of Labcorp’s former clinical-development business.

Capability	Buyer should compare	Fortrea readout
Site selection and feasibility	Therapy-area site relationships, country mix, site activation timelines, and feasibility analytics.	Core site-selection work. Fortrea operates as a global CRO across roughly 100 countries; validate current site relationships and delivery leads by protocol and geography.
Patient recruitment and retention	Referral workflows, screening, patient support during study conduct, and dropout reduction.	Recruitment work. Recruitment is part of the CRO scope, but hub-style patient access and affordability programs now sit outside Fortrea.
Data management and biostatistics	EDC, data quality, statistical programming, biostatistics, and clinical data standards.	Trial data work. Standard global CRO scope; ask which systems and reporting layers are used for the proposed engagement.
Clinical operations and monitoring	Monitoring model, FSP, hybrid sourcing, GCP controls, and risk-based monitoring.	Core clinical operations. Fortrea offers full-service, FSP, and hybrid delivery models; governance fit is a central diligence item.
Real-world evidence and HEOR	Late-phase studies, RWE generation, HEOR, payer evidence packages, and value dossiers.	Supporting capability. Fortrea can support evidence-generation and HEOR strategy, especially for biotech sponsors, but it is not a specialist managed-markets agency.
Regulatory and submission support	Regulatory strategy, agency interactions, submission planning, and global filing support.	Regulatory support. Regulatory strategy is part of the development-services scope; confirm therapy-specific references and country coverage.
Trial-to-commercial continuity	Continuity planning for patients, access transition, hub handoff, and early commercial operations.	Boundary-sensitive. Fortrea can support evidence and development-to-launch planning, but divested patient-access services now route to Neovance.

Buyer Fit

• When it belongs in the set: Sponsors needing global CRO execution, FSP or hybrid resourcing, clinical pharmacology, regulatory strategy, and evidence-generation support.
• Best-fit buyers: Mid-to-large pharma and emerging biotech sponsors with complex global protocols, early-development needs, or evidence-pathway diligence.
• Less ideal fit: Programs that primarily need hub services, specialty pharmacy, non-commercial dispensing, copay / PAP operations, or reimbursement casework.
• Operating model: Custom/RFP. Decide early whether Fortrea is the full-service CRO, an FSP partner, a clinical pharmacology partner, or a narrower evidence / consulting contributor.
• Commercial diligence: Delivery leadership, site activation history, change-order discipline, FSP governance, clinical pharmacology unit fit, technology deployment, customer concentration risk, and current therapeutic-area references.

Differentiators

• Public pure-play CRO after Labcorp spin-off: Fortrea gives buyers more disclosure visibility than private CRO peers while retaining Labcorp / Covance clinical-development heritage.
• Clinical pharmacology footprint: Four clinical research units support early-phase, first-in-human, and clinical pharmacology work that smaller CROs may not cover directly.
• Full-service, FSP, and hybrid delivery: Sponsors can choose a traditional full-service CRO model, functional resourcing, or a blended model.
• Fortrea Intelligent Technology: AI-assisted trial-operations suite launched in 2026 for workflow automation, predictive risk mitigation, and study-team support.
• Clean access-services boundary: The divested patient-access business is no longer part of Fortrea, reducing confusion if the buyer distinguishes CRO work from hub / access operations.

RFP Questions

• Which delivery leaders, therapeutic leads, and site networks would be assigned to this protocol?
• What recent program references match the therapy area, phase, geography, and sponsor size?
• Which work belongs in full-service CRO scope versus FSP, hybrid resourcing, clinical pharmacology, or consulting?
• How are site activation, monitoring, data management, biostatistics, medical writing, pharmacovigilance, and regulatory work governed?
• What change-order controls, pass-through cost discipline, and escalation rights apply?
• Which Fortrea Intelligent Technology modules are in production for the proposed work, and what evidence shows they improve trial execution?
• What if launch planning or access handoff is in scope, where does Fortrea’s evidence / regulatory work end and where should a separate hub, specialty pharmacy, or patient-services vendor begin?

Recent Activity

• 2026-05: Fortrea reported Q1 2026 backlog of $7.846B, quarterly book-to-bill of 1.15x, and trailing twelve-month book-to-bill of 1.05x.
• 2026-04: Fortrea launched Fortrea Intelligent Technology, an AI-assisted suite for more integrated trial operations.
• 2024-06: Fortrea completed the divestiture of Endpoint Clinical and the patient-access business to Arsenal Capital Partners, narrowing the current company around CRO services.
• 2023-06: Labcorp completed the Fortrea spin-off, creating an independent public CRO.